Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Short-chain fatty acids affect immune cell function, leading to changes in the levels of released cytokines and reactive oxygen species
Management emphasizes consistent lid hygiene, warm compresses, and occasionally topical antibiotics
Log in Sign up
There is a chance that peptides besides GLP-1s will eventually be demonstrated to provide health outcome benefits as seen in rodent pre-clinical models
GHK-Cu and Rosuvastatin Interaction: Safety, Mechanisms, and Clinical Guidance At a glance Direct interaction evidence / none published as of May 2026 GHK-Cu metabolism / peptidase degradation, not CYP-mediated Rosuvastatin metabolism / minimal CYP2C9, primarily OATP1B1/1B3 hepatic uptake Overlapping CYP liability / none identified Copper load concern / low at typical GHK-Cu doses (1-3 mg/day subcutaneous) Rosuvastatin muscle risk / myopathy incidence approximately 0.1% per FDA label Monitoring recommendation / CK at baseline and if symptoms arise
